IP Library Granted Patent US 10,226,506
Granted Patent B2
US 10,226,506 · App. 15/833,544 · Granted Mar 12, 2019

Treatment and diagnosis of inflammatory disorders and HIV

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,226,506
App. No.
15/833,544
Granted
Mar 12, 2019
Kind
B2
Abstract

This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV.

Claims (4)

1. A method of treating an inflammatory autoimmune disease characterized by an influx of immune cells into the central nervous system, the method consisting essentially of administering to a subject in need thereof, a therapeutically effective amount of a leukotoxin comprising SEQ ID NO: 1, wherein the inflammatory autoimmune disease is multiple sclerosis which is characterized by upregulated expression of leukocyte function antigen-1 (LFA-1) on the surface of activated immune cells from blood and cerebrospinal fluid of the subject, wherein the leukotoxin depletes and/or blocks the activated immune cells in the central nervous system of the subject.

2. The method of claim 1 , wherein the leukotoxin is prepared from Aggregatibacter actinomycetemcomitans.

3. A method of treating an inflammatory autoimmune disease characterized by an influx of immune cells into the central nervous system, the method consisting of administering to a subject in need thereof a therapeutically effective amount of a leukotoxin comprising SEQ ID NO: 1, wherein the inflammatory autoimmune disease is multiple sclerosis which is characterized by upregulated expression of leukocyte function antigen-1 (LFA-1) on the surface of activated immune cells from blood and cerebrospinal fluid of the subject, wherein the leukotoxin depletes and/or blocks the activated immune cells in the central nervous system of the subject.

4. The method of claim 2 , wherein the leukotoxin is prepared from Aggregatibacter actinomycetemcomitans.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2024
From: ACTINOBAC BIOMED, INC.
To: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Reel/Frame 067213/0348 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2018
From: BELINKA, BENJAMIN
To: ACTINOBAC BIOMED, INC.
Reel/Frame 047604/0602 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2018
From: KACHLANY, SCOTT
To: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Reel/Frame 047604/0706 →